Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Interest Expense

Cost of servicing the company's debt during the period.

Canopy Growth CorporationNASDAQ: CGC

Interest Expense · Q4 FY2025 · quarter ended Mar 2026

Interest expense declines year over year

Q4 FY2025 interest expense of CA$12.31M fell 20.0% year over year, ahead of the -45.1% change in trailing-twelve-month interest expense. Sequentially, it rose 22.3% from the prior quarter. Over 3 fiscal years it compounded at -32.9% a year.

Context

  • Interest expense amounted to 7.9% of revenue in FY2025, down 19.8 pp from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.0% holds above the trailing-twelve-month pace of -45.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$12.31M+22.3% QoQ
Last fiscal yearMar 2026
CA$38.19M-48.8% YoY
LTMMar 2026
CA$40.92M-45.1% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.0%——
1 year-48.8%——
3-year CAGR-32.9%——
5-year CAGR——
10-year CAGR——

Interest Expense history

CAD · from the income statement

Latest · FY2025
38.19M CAD
Year-over-year change
-48.8%
4-year CAGR
-22.1%

Interest Expense vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.1% is the 6th highest of 7, against a peer median of -7.4%.
  • Interest expense amounts to 13.1% of revenue for CGC, versus a peer median of 3.3%.
CGC Competitors
Interest Expense for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$40.92M CAD-45.1%-32.9%13.1%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$33.82M USD-0.2%+62.7%9.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$22.88M USD—+12.0%16.9%
DHDefinitive Healthcare Corp.LTM Mar 2026$11.48M USD-14.6%+0.3%4.8%
ACBAurora Cannabis Inc.LTM Mar 2026CA$5.82M CAD-30.9%-64.2%1.9%
CABACabaletta Bio, Inc.LTM Mar 2026$2.35M USD+125.1%——
TKNOAlpha Teknova, Inc.LTM Mar 2026$785K USD+14.4%—1.9%
BIOABioAge Labs, Inc.LTM Mar 2026$481K USD-65.8%+42.5%4.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CGC) —-7.4%+12.0%3.3%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.